GlassScriptPhysician profile
Rebeca Kane
NPI 1144343864
$5,327.37
in general payments reported to CMS, 2019-2025
31 companies · $2,494 in 2025
The $2,494 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $413 · 2023: $928 · 2024: $1,357 · 2025: $2,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,810 · Travel and Lodging: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,810.48 |
| Travel and Lodging | $968.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,262.44 | 2025 | |
| Abiomed | $672.14 | 2023-2024 | Impella |
| Cvrx, INC. | $480.87 | 2024-2025 | Barostim Neo System |
| Abbott Laboratories | $403.70 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $369.37 | 2023-2025 | |
| Amgen INC. | $297.86 | 2021-2025 | Repatha |
| Paragonix Technologies, INC. | $240.81 | 2024 | Pancreaspak, Baroguard, Liverguard |
| Impulse Dynamics (USA) INC. | $196.03 | 2022-2025 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $188.15 | 2022-2024 | Farxiga, Wainua |
| Boston Scientific Corporation | $146.94 | 2024 | |
| Mylan Specialty L.P. | $111.54 | 2022-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $107.18 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Shockwave Medical, INC | $99.66 | 2025 | |
| Merck Sharp & Dohme LLC | $92.34 | 2024-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.72 | 2022-2025 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.65 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $64.50 | 2022-2025 | Onpattro, Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $57.01 | 2021-2025 | |
| Scpharmaceuticals INC. | $55.30 | 2024-2025 | |
| Atricure, INC. | $52.48 | 2025 | Atriclip Laa Exclusion System |
| Glaxosmithkline, LLC. | $50.45 | 2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $41.42 | 2021-2024 | Livtencity |
| Genzyme Corporation | $30.00 | 2022 | |
| Daxor Corporation | $28.80 | 2023 | Bva-100 |
| One Lambda, INC. | $28.20 | 2024 | |
| Endotronix, INC. | $21.30 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Janssen Pharmaceuticals, INC | $16.25 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $15.69 | 2024 | Camzyos |
| Medtronic, INC. | $15.27 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $15.18 | 2023 | Arcalyst |
| Invivyd INC | $15.12 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebeca Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.